MediLink Therapeutics has cleared its Investigational New Drug (IND) application for YL217, an investigational antibody-drug conjugate (ADC) developed by MediLink. YL217 is the 11th ADC candidate entering into clinical stage developed based on MediLink’s proprietary TMALIN® technology platform. #IND #ADC #Clinical #FDA #NMPA #YL217 #TMALIN
关于我们
AsymBio is the core unit of the newly established strategic business segment within Asymchem Group (Stock Code: 002821.SZ/6821.HK). AsymBio is committed to becoming a technology-driven, one-stop services CDMO company for biologics development/production that can deliver efficient, customizable and extensive high-quality services to our clients. Our all-round and personalized services offer comprehensive capabilities covering process development, product manufacturing, fill-finish, analytical development and testing, domestic and oversea regulatory registration and submission filings for a broad range of novel biopharmaceuticals including antibodies, recombinant biotherapeutics, bioconjugates, plasmids and mRNAs. AsymBio operates following a flexible and cooperative business model with the motto of “customer-first, quality-first” to achieve win-win outcomes along with our clients. Asymbio is a trusted partner to global innovative biopharmaceutical companies of all sizes, empowering the progress of biopharmaceutical industry with our innovative technologies and platform solutions that are continuously under optimization. We strive to be a partner of choice in global drug R&D and production, starting with every client, every product, and every service.
- 所属行业
- 制药业
- 规模
- 501-1,000 人
- 总部
- Shanghai
- 类型
- 上市公司
地点
-
主要
获取路线
Jinshan Industrial Park
CN，Shanghai
AsymBio员工
动态
-
Lepu Biopharma Co., Ltd. has entered an exclusive licensing agreement with ArriVent Biopharma, Inc. to develop and commercialize its novel ADC candidate, MRG007, outside the Greater China region. This agreement allows ArriVent to leverage Lepu’s intellectual property for MRG007, a promising treatment for gastrointestinal cancers, potentially yielding up to $1.16 billion in milestone payments for Lepu. This partnership is expected to enhance Lepu’s global presence and maximize its pipeline and commercial value. #ADC #Lepu #MRG007 #development #commercialization #global #China Source: official statement
-
-
MediLink Therapeutics has entered into a new strategic collaboration and worldwide license agreement with Zai Lab to use MediLink’s TMALIN antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Leucine-rich repeat-containing protein 15 (LRRC15) is a type I transmembrane protein involved in cell-cell and cell-extracellular matrix (ECM) interactions, which is an appealing target for cancer therapy. #ADC #MediLink #LRRC15 #cancer #therapy #antibody
-
-
Axcynsis Therapeutics, a strategic partner of AsymBio, announced the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors. Axcynsis is planning to initiate a Phase 1 multicentre clinical trial in the United States in 1Q 2025. We look forward to continuing our collaboration to advance clinical trials and address unmet medical needs for patients worldwide. #ADC #IND #FDA #CLDN6 #clinical #CDMO #AsymBio #payload #linker
-
-
We are here at Biotech Showcase! Stop by our table to discuss potential collaborations in 2025 and beyond! #biotechshowcase #CDMO #biologics #ADC #development #manufacturing #JPM
-
-
AsymBio will be on site in Biotech Showcase, which is the epicenter of the life science ecosystem, to demonstrate leading ADC CDMO solutions. From groundbreaking breakthroughs to strategic partnerships, it’s all happening here. #ADC #JPM #BiotechShowcase #biopharma #pharma #biopartnering
-
-
Duality Biologics has announced a $1.2-billion licensing pact with Avenzo Therapeutics for an EGFR/HER3 bispecific ADC set to enter clinical testing this year. The deal follows DualityBio's B7-H3-targeted ADC partnership with BioNTech and a recent option agreement with GSK. Avenzo will gains exclusive global rights to develop, manufacture, and commercialise AVZO-1418/DB-1418 except China. The San Diego-based company will pay DualityBio $50 million upfront, with potential milestone payments reaching approximately $1.15 billion, plus tiered royalties on sales. Source: DualityBio's statement Follow AsymBio for integrated ADC CDMO solutions!
-
-
Certain types of ADCs are light-sensitive, which may cause compromised DP quality. AsymBio offers comprehensive formulation development solutions. Our IMPACT platform is capable of designing light control strategies during DS/DP manufacturing, storage and delivery. #ADC #DP #IMPACT #formulation #Drug_Product #DPD #CDMO #Development
-
-
Innovent Biologics has signed a collaboration and exclusive license agreement with Roche to advance the development of IBI3009, a type of DLL3 ADC. Under the agreement, Roche will obtain exclusive global rights to develop, manufacture and commercialise IBI3009. The two companies will work together on the early-stage development of this ADC candidate, and Roche will take over full development. #ADC #Innovent #Roche #DLL3 #global #development #commercialization #manufacturing Follow AsymBio for more info on ADC integrated CDMO solutions!
-